Adma Biologics Long Term Debt

As of the most recent data (June 2026), ADMA shows a long-term debt of $200M. That compares with $83M in the prior-year period — up 140.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ADMA's long-term debt is now $200M (was $83M) — a 140.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Adma Biologics is outperforming or lagging.

Tracking ADMA's long-term debt over time shows whether Adma Biologics is scaling, shrinking, or reshaping that part of the business. The current reading is $200M That compares with $83M in the prior-year period — up 140.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Adma Biologics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $200M) with ownership activity and broader fundamentals.

Adma Biologics's long-term debt is $200M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.